CLEARY TG; Interscience Conference on Antimicrobial Agents and Chemotherapy (42nd : 2002 : San Diego, Calif.).
Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2002 Sep 27-30; 42: abstract no. 1547.
Univ. of Texas Med. Sch, Houston, TX.
Shiga toxin [Stx] producing E. coli [STEC] cause a spectrum of illnesses that includes watery diarrhea, hemorrhagic colitis [HC], and vascular endothelial injury with thrombocytopenia, hemolytic anemia, and acute renal failure. The most common STEC in North America is serotype O157:H7. Prevention of hemolytic uremic syndrome [HUS] might be achieved by public health measures that decrease the risk of infection. However, the low inoculum size required to cause illness and the multiple potential vehicles for infection suggests that either an immunization strategy or measures that block the cascade of events that results in HUS is worth investigation. Typically, there is an interval between onset of bloody diarrhea and development of HUS. This interval presents an opportunity for intervention. The focus of this talk will be on the pathophysiology of HC/HUS and measures that might stop the process. The practical issues related to frequency of infection, sample size, and logistics of arriving at an effective therapy will be addressed.
Publication Types:
Keywords:
- Anemia, Hemolytic
- Colitis
- Communicable Diseases
- Diarrhea
- Escherichia coli
- Escherichia coli Infections
- Hemolytic-Uremic Syndrome
- Kidney Failure, Acute
- North America
- Shiga Toxin
- methods
- therapy
Other ID:
UI: 102268063
From Meeting Abstracts